Article: FDA Approves Risperdal for Treatment of Bipolar Mania.

Byline: Feinstein Kean Healthcare

TITUSVILLE, N.J., Dec. 5 (AScribe Newswire) -- The U.S. Food and Drug Administration (FDA) has approved Risperdal(R) (risperidone) as monotherapy (alone) or in combination with lithium or valproate for the short-term treatment of acute manic or mixed episodes associated with bipolar I disorder, also known as bipolar mania. In research studies, patients with bipolar mania who took Risperdal showed significant improvement in manic symptoms compared to placebo.

Bipolar disorder affects more than 2 million people in the United States and is characterized by dramatic mood swings, alternating between the highs of mania and the ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!